Review



anti goat cd13  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    R&D Systems anti goat cd13
    a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, <t>Cd13-positive</t> immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.
    Anti Goat Cd13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 122 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+goat+cd13/Mouse+Aminopeptidase+N%2FCD13+Antibody/bio_rxiv__64898__2026__02__28__708735-284-22-24
    Average 96 stars, based on 122 article reviews
    anti goat cd13 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice"

    Article Title: Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice

    Journal: bioRxiv

    doi: 10.64898/2026.02.28.708735

    a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, Cd13-positive immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.
    Figure Legend Snippet: a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, Cd13-positive immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.

    Techniques Used: Comparison

    a. Mean Open field (OF) locomotion scores for the saline and coacervate treated SCI mice over two weeks. **p value < 0.005, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test. b. Grid walk (GW) test performance for the saline and coacervate treated SCI mice over two weeks, **p value < 0.0001, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. c. Correlation analysis of OF and GW scores for carrier injected SCI mice, with the behavioral tests showing strong positive correlation (r=0.86), p-value <0.0001, t-test for Pearson’s linear correlation. d. Pie charts indicating the AFS subgroup distribution across the saline and coacervate injected SCI mice. e. Mean OF, GW and combined assessment PMP values for the AFS designation separated by carrier injection type. f. Confusion matrix showing the percentage of mice displaying Class 1, 2 and 3 type recovery from the three AFS subgroups based on the combined evaluation of OF and GW testing results. g. Representative survey IHC images of carrier treated SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes and Cd13-positive immune and stromal cells. h. Quantification of SCI lesion size at 14 days after SCI stratified by subgroup and carrier injection. *p value < 0.05, Two-way ANOVA with Tukey multiple comparison test. i. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup and carrier injection., *p value < 0.02, Two-way ANOVA with Tukey multiple comparison test.
    Figure Legend Snippet: a. Mean Open field (OF) locomotion scores for the saline and coacervate treated SCI mice over two weeks. **p value < 0.005, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test. b. Grid walk (GW) test performance for the saline and coacervate treated SCI mice over two weeks, **p value < 0.0001, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. c. Correlation analysis of OF and GW scores for carrier injected SCI mice, with the behavioral tests showing strong positive correlation (r=0.86), p-value <0.0001, t-test for Pearson’s linear correlation. d. Pie charts indicating the AFS subgroup distribution across the saline and coacervate injected SCI mice. e. Mean OF, GW and combined assessment PMP values for the AFS designation separated by carrier injection type. f. Confusion matrix showing the percentage of mice displaying Class 1, 2 and 3 type recovery from the three AFS subgroups based on the combined evaluation of OF and GW testing results. g. Representative survey IHC images of carrier treated SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes and Cd13-positive immune and stromal cells. h. Quantification of SCI lesion size at 14 days after SCI stratified by subgroup and carrier injection. *p value < 0.05, Two-way ANOVA with Tukey multiple comparison test. i. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup and carrier injection., *p value < 0.02, Two-way ANOVA with Tukey multiple comparison test.

    Techniques Used: Saline, Comparison, Injection

    Related Articles

    Comparison:

    Article Title: Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice
    Article Snippet: Following 1N HCl antigen retrieval and serial washes, the tissue sections were blocked and permeabilized using 1× TBS containing 5% Normal donkey serum (NDS, Jackson ImmunoResearch Laboratories) and 0.5% Triton x-100 for 1 h. Tissue sections were then stained with primary antibodies overnight in 1× TBS containing 0.5 % Triton X-100.serial washes, the tissue sections were blocked and permeabilized using 1× TBS containing 5% Normal donkey serum (NDS, Jackson ImmunoResearch Laboratories) and 0.5% Triton x-100 for 1 h. Tissue sections were then stained with primary antibodies overnight in 1× TBS containing 0.5 % Triton X-100. ... The following primary antibodies were used in this study: anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea Pig Gfap (Synaptic Systems, 173 308, 1:500); anti-Goat Cd13 (R&D systems, AF2335, 1:500), anti-Rabbit 5-HT (Serotonin) (Immunostar, #20080, 1:1000); anti- Rat MBP (Sigma, MAB386, 1:500).. Tissue sections were washed three times and incubated with appropriate secondary antibodies diluted at 1:250 in 1X TBS containing 0.5 % Triton X-100 and 5 % NDS for 2 h. All secondary antibodies were affinity purified whole IgG (H + L) purchased from Jackson ImmunoResearch Laboratories, with donkey host and target specified by the primary antibody.Tissue sections were washed three times and incubated with appropriate secondary antibodies diluted at 1:250 in 1X TBS containing 0.5 % Triton X-100 and 5 % NDS for 2 h. All secondary antibodies were affinity purified whole IgG (H + L) purchased from Jackson ImmunoResearch..

    Article Title: Trehalose-based coacervates for local bioactive protein delivery to the central nervous system.
    Article Snippet: and 0.5 % Triton x-100 for 1 h. Tissue sections were then stained with primary antibodies overnight in 1× TBS containing 0.5 % Triton x-100. .. The following primary antibodies were used in this study: anti-Rabbit NeuN (Abcam, ab177487, 1:1000); anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea pig Iba-1 (Synaptic Systems, 234,004, 1:500); anti-Rabbit P2ry12 (Ana Spec, AS-55043A, 1:800); anti-Goat Cd13 (R&D systems, AF2335, 1:500); anti-Rat Ly6b2 (BioRad, MCA771G, 1:200); anti-Goat ChAT (MilliporeSigma, AB144P, 1:500). .. Tissue sections were washed three times and incubated with appropriate secondary antibodies diluted at 1:250 in 1× TBS containing 0.5 % Triton x-100 a

    Article Title: Trehalose-based coacervates for local bioactive protein delivery to the central nervous system
    Article Snippet: sections were then stained with primary antibodies overnight in 1X TBS containing 0.5% Triton x-100. .. The following primary antibodies were used in this study: anti-Rabbit NeuN (Abcam, ab177487, 1:1000); anti-Rat Gfap (Invitrogen, 13-0300, 1:1000); anti-Guinea pig Iba-1 (Synaptic Systems, 234 004, 1:500); anti-Rabbit P2ry12 (Ana Spec, AS-55043A, 1:800); anti-Goat Cd13 (R&D systems, AF2335, 1:500); anti-Rat Ly6b2 (BioRad, MCA771G, 1:200); anti-Goat ChAT (MilliporeSigma, AB144P, 1:500). .. Tissue sections were washed three times and incubated with appropriate sec-ondary antibodies diluted at 1:2

    Saline:

    Article Title: Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice
    Article Snippet: Following 1N HCl antigen retrieval and serial washes, the tissue sections were blocked and permeabilized using 1× TBS containing 5% Normal donkey serum (NDS, Jackson ImmunoResearch Laboratories) and 0.5% Triton x-100 for 1 h. Tissue sections were then stained with primary antibodies overnight in 1× TBS containing 0.5 % Triton X-100.serial washes, the tissue sections were blocked and permeabilized using 1× TBS containing 5% Normal donkey serum (NDS, Jackson ImmunoResearch Laboratories) and 0.5% Triton x-100 for 1 h. Tissue sections were then stained with primary antibodies overnight in 1× TBS containing 0.5 % Triton X-100. ... The following primary antibodies were used in this study: anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea Pig Gfap (Synaptic Systems, 173 308, 1:500); anti-Goat Cd13 (R&D systems, AF2335, 1:500), anti-Rabbit 5-HT (Serotonin) (Immunostar, #20080, 1:1000); anti- Rat MBP (Sigma, MAB386, 1:500).. Tissue sections were washed three times and incubated with appropriate secondary antibodies diluted at 1:250 in 1X TBS containing 0.5 % Triton X-100 and 5 % NDS for 2 h. All secondary antibodies were affinity purified whole IgG (H + L) purchased from Jackson ImmunoResearch Laboratories, with donkey host and target specified by the primary antibody.Tissue sections were washed three times and incubated with appropriate secondary antibodies diluted at 1:250 in 1X TBS containing 0.5 % Triton X-100 and 5 % NDS for 2 h. All secondary antibodies were affinity purified whole IgG (H + L) purchased from Jackson ImmunoResearch..

    Article Title: Trehalose-based coacervates for local bioactive protein delivery to the central nervous system.
    Article Snippet: and 0.5 % Triton x-100 for 1 h. Tissue sections were then stained with primary antibodies overnight in 1× TBS containing 0.5 % Triton x-100. .. The following primary antibodies were used in this study: anti-Rabbit NeuN (Abcam, ab177487, 1:1000); anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea pig Iba-1 (Synaptic Systems, 234,004, 1:500); anti-Rabbit P2ry12 (Ana Spec, AS-55043A, 1:800); anti-Goat Cd13 (R&D systems, AF2335, 1:500); anti-Rat Ly6b2 (BioRad, MCA771G, 1:200); anti-Goat ChAT (MilliporeSigma, AB144P, 1:500). .. Tissue sections were washed three times and incubated with appropriate secondary antibodies diluted at 1:250 in 1× TBS containing 0.5 % Triton x-100 a

    Article Title: Trehalose-based coacervates for local bioactive protein delivery to the central nervous system
    Article Snippet: sections were then stained with primary antibodies overnight in 1X TBS containing 0.5% Triton x-100. .. The following primary antibodies were used in this study: anti-Rabbit NeuN (Abcam, ab177487, 1:1000); anti-Rat Gfap (Invitrogen, 13-0300, 1:1000); anti-Guinea pig Iba-1 (Synaptic Systems, 234 004, 1:500); anti-Rabbit P2ry12 (Ana Spec, AS-55043A, 1:800); anti-Goat Cd13 (R&D systems, AF2335, 1:500); anti-Rat Ly6b2 (BioRad, MCA771G, 1:200); anti-Goat ChAT (MilliporeSigma, AB144P, 1:500). .. Tissue sections were washed three times and incubated with appropriate sec-ondary antibodies diluted at 1:2

    Injection:

    Article Title: Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice
    Article Snippet: Following 1N HCl antigen retrieval and serial washes, the tissue sections were blocked and permeabilized using 1× TBS containing 5% Normal donkey serum (NDS, Jackson ImmunoResearch Laboratories) and 0.5% Triton x-100 for 1 h. Tissue sections were then stained with primary antibodies overnight in 1× TBS containing 0.5 % Triton X-100.serial washes, the tissue sections were blocked and permeabilized using 1× TBS containing 5% Normal donkey serum (NDS, Jackson ImmunoResearch Laboratories) and 0.5% Triton x-100 for 1 h. Tissue sections were then stained with primary antibodies overnight in 1× TBS containing 0.5 % Triton X-100. ... The following primary antibodies were used in this study: anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea Pig Gfap (Synaptic Systems, 173 308, 1:500); anti-Goat Cd13 (R&D systems, AF2335, 1:500), anti-Rabbit 5-HT (Serotonin) (Immunostar, #20080, 1:1000); anti- Rat MBP (Sigma, MAB386, 1:500).. Tissue sections were washed three times and incubated with appropriate secondary antibodies diluted at 1:250 in 1X TBS containing 0.5 % Triton X-100 and 5 % NDS for 2 h. All secondary antibodies were affinity purified whole IgG (H + L) purchased from Jackson ImmunoResearch Laboratories, with donkey host and target specified by the primary antibody.Tissue sections were washed three times and incubated with appropriate secondary antibodies diluted at 1:250 in 1X TBS containing 0.5 % Triton X-100 and 5 % NDS for 2 h. All secondary antibodies were affinity purified whole IgG (H + L) purchased from Jackson ImmunoResearch..

    Article Title: Trehalose-based coacervates for local bioactive protein delivery to the central nervous system.
    Article Snippet: and 0.5 % Triton x-100 for 1 h. Tissue sections were then stained with primary antibodies overnight in 1× TBS containing 0.5 % Triton x-100. .. The following primary antibodies were used in this study: anti-Rabbit NeuN (Abcam, ab177487, 1:1000); anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea pig Iba-1 (Synaptic Systems, 234,004, 1:500); anti-Rabbit P2ry12 (Ana Spec, AS-55043A, 1:800); anti-Goat Cd13 (R&D systems, AF2335, 1:500); anti-Rat Ly6b2 (BioRad, MCA771G, 1:200); anti-Goat ChAT (MilliporeSigma, AB144P, 1:500). .. Tissue sections were washed three times and incubated with appropriate secondary antibodies diluted at 1:250 in 1× TBS containing 0.5 % Triton x-100 a

    Article Title: Trehalose-based coacervates for local bioactive protein delivery to the central nervous system
    Article Snippet: sections were then stained with primary antibodies overnight in 1X TBS containing 0.5% Triton x-100. .. The following primary antibodies were used in this study: anti-Rabbit NeuN (Abcam, ab177487, 1:1000); anti-Rat Gfap (Invitrogen, 13-0300, 1:1000); anti-Guinea pig Iba-1 (Synaptic Systems, 234 004, 1:500); anti-Rabbit P2ry12 (Ana Spec, AS-55043A, 1:800); anti-Goat Cd13 (R&D systems, AF2335, 1:500); anti-Rat Ly6b2 (BioRad, MCA771G, 1:200); anti-Goat ChAT (MilliporeSigma, AB144P, 1:500). .. Tissue sections were washed three times and incubated with appropriate sec-ondary antibodies diluted at 1:2



    Similar Products

    anti goat cd13  (R&D Systems)
    96
    R&D Systems anti goat cd13
    a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, <t>Cd13-positive</t> immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.
    Anti Goat Cd13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+goat+cd13/Mouse+Aminopeptidase+N%2FCD13+Antibody/bio_rxiv__64898__2026__02__28__708735-284-22-24
    Average 96 stars, based on 1 article reviews
    anti goat cd13 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    af2335 donkey anti goat 568  (R&D Systems)
    96
    R&D Systems af2335 donkey anti goat 568
    a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, <t>Cd13-positive</t> immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.
    Af2335 Donkey Anti Goat 568, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+goat+cd13/Mouse+Aminopeptidase+N%2FCD13+Antibody/pm41688665-416-62-60
    Average 96 stars, based on 1 article reviews
    af2335 donkey anti goat 568 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    dl 1174 pericytes goat anti cd13  (Vector Laboratories)
    96
    Vector Laboratories dl 1174 pericytes goat anti cd13
    a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, <t>Cd13-positive</t> immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.
    Dl 1174 Pericytes Goat Anti Cd13, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+goat+cd13/DyLight+488+Labeled+Lycopersicon+Esculentum+(Tomato)+Lectin+(LEL%2C+TL)/pm41688665-416-55-53
    Average 96 stars, based on 1 article reviews
    dl 1174 pericytes goat anti cd13 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    goat anti cd13  (R&D Systems)
    96
    R&D Systems goat anti cd13
    a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, <t>Cd13-positive</t> immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.
    Goat Anti Cd13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+goat+cd13/Mouse+Aminopeptidase+N%2FCD13+Antibody/bio_rxiv__64898__2025__12__19__695391-67-84-87
    Average 96 stars, based on 1 article reviews
    goat anti cd13 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    goat anti cd13 polyclonal antibody  (R&D Systems)
    96
    R&D Systems goat anti cd13 polyclonal antibody
    a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, <t>Cd13-positive</t> immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.
    Goat Anti Cd13 Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+goat+cd13/Mouse+Aminopeptidase+N%2FCD13+Antibody/pm41427883-87-6-13
    Average 96 stars, based on 1 article reviews
    goat anti cd13 polyclonal antibody - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    goat anti aminopeptidase n  (R&D Systems)
    96
    R&D Systems goat anti aminopeptidase n
    a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, <t>Cd13-positive</t> immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.
    Goat Anti Aminopeptidase N, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+goat+cd13/Mouse+Aminopeptidase+N%2FCD13+Antibody/pm40835053-67-14-20
    Average 96 stars, based on 1 article reviews
    goat anti aminopeptidase n - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    polyclonal goat anti mouse aminopeptidase n cd13  (R&D Systems)
    96
    R&D Systems polyclonal goat anti mouse aminopeptidase n cd13
    a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, <t>Cd13-positive</t> immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.
    Polyclonal Goat Anti Mouse Aminopeptidase N Cd13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+goat+cd13/Mouse+Aminopeptidase+N%2FCD13+Antibody/pmc12411274__41593_2025_2023_MOESM2_ESM-63-137-142
    Average 96 stars, based on 1 article reviews
    polyclonal goat anti mouse aminopeptidase n cd13 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    goat anti mouse aminopeptidase n anpep cd13  (R&D Systems)
    96
    R&D Systems goat anti mouse aminopeptidase n anpep cd13
    a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, <t>Cd13-positive</t> immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.
    Goat Anti Mouse Aminopeptidase N Anpep Cd13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+goat+cd13/Mouse+Aminopeptidase+N%2FCD13+Antibody/pm40738972-356-43-48
    Average 96 stars, based on 1 article reviews
    goat anti mouse aminopeptidase n anpep cd13 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    goat anti mouse aminopeptidase n cd13  (R&D Systems)
    88
    R&D Systems goat anti mouse aminopeptidase n cd13
    FIGURE 3 | Revascularization is stabilized by VEGF-E associated with attenuation of neuronal degeneration. (a) Representative fluorescence images of CD31 and PDGFRβ immunolabeling at the injury site in vehicle (VEH)- and VEGF-E-treated mice 4 days after stroke. (b) Analysis of the density of perivascular PDGFRβ+ cells at the injury site 4 days after stroke. (c) Analysis of CD31 and PDGFRβ colocalization at the injury site. (d) Analysis of the number of CD31+ microvascular stalls at the injury site. (e) Representative fluorescence images of <t>CD13</t> and CD105 immunolabeling at the injury site in VEH- and VEGF-E-treated mice. (f) Analysis of the density of CD105+ microvessels at the injury site. (g) Analysis of CD105 and CD13 colocalization at the injury site. (h) Representative fluorescence images of FJB+ degenerating neurons in the ipsilateral cortex and ipsilateral striatum. Stereological analysis of the density of FJB+ degenerating neurons in the (i) ipsilateral cortex and (j) ipsilateral striatum. Data are boxplot with min/max or stacked histogram (n = 6–7 animals/group). *p < 0.05, **p < 0.01, ***p < 0.001 compared to control (b, d, f, i, unpaired two-tailed t- test). Abbreviations: IF, immunofluorescence; VEGF, vascular endothelial growth factor; VEH, vehicle.
    Goat Anti Mouse Aminopeptidase N Cd13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+goat+cd13/Mouse+Aminopeptidase+N%2FCD13+Biotinylated+Antibody/pm40277075-110-19-26
    Average 88 stars, based on 1 article reviews
    goat anti mouse aminopeptidase n cd13 - by Bioz Stars, 2026-10
    88/100 stars
    		  Buy from Supplier

    Image Search Results


    a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, Cd13-positive immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.

    Journal: bioRxiv

    Article Title: Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice

    doi: 10.64898/2026.02.28.708735

    Figure Lengend Snippet: a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, Cd13-positive immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.

    Article Snippet: The following primary antibodies were used in this study: anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea Pig Gfap (Synaptic Systems, 173 308, 1:500); anti-Goat Cd13 (R&D systems, AF2335, 1:500), anti-Rabbit 5-HT (Serotonin) (Immunostar, #20080, 1:1000); anti- Rat MBP (Sigma, MAB386, 1:500).

    Techniques: Comparison

    a. Mean Open field (OF) locomotion scores for the saline and coacervate treated SCI mice over two weeks. **p value < 0.005, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test. b. Grid walk (GW) test performance for the saline and coacervate treated SCI mice over two weeks, **p value < 0.0001, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. c. Correlation analysis of OF and GW scores for carrier injected SCI mice, with the behavioral tests showing strong positive correlation (r=0.86), p-value <0.0001, t-test for Pearson’s linear correlation. d. Pie charts indicating the AFS subgroup distribution across the saline and coacervate injected SCI mice. e. Mean OF, GW and combined assessment PMP values for the AFS designation separated by carrier injection type. f. Confusion matrix showing the percentage of mice displaying Class 1, 2 and 3 type recovery from the three AFS subgroups based on the combined evaluation of OF and GW testing results. g. Representative survey IHC images of carrier treated SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes and Cd13-positive immune and stromal cells. h. Quantification of SCI lesion size at 14 days after SCI stratified by subgroup and carrier injection. *p value < 0.05, Two-way ANOVA with Tukey multiple comparison test. i. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup and carrier injection., *p value < 0.02, Two-way ANOVA with Tukey multiple comparison test.

    Journal: bioRxiv

    Article Title: Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice

    doi: 10.64898/2026.02.28.708735

    Figure Lengend Snippet: a. Mean Open field (OF) locomotion scores for the saline and coacervate treated SCI mice over two weeks. **p value < 0.005, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test. b. Grid walk (GW) test performance for the saline and coacervate treated SCI mice over two weeks, **p value < 0.0001, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. c. Correlation analysis of OF and GW scores for carrier injected SCI mice, with the behavioral tests showing strong positive correlation (r=0.86), p-value <0.0001, t-test for Pearson’s linear correlation. d. Pie charts indicating the AFS subgroup distribution across the saline and coacervate injected SCI mice. e. Mean OF, GW and combined assessment PMP values for the AFS designation separated by carrier injection type. f. Confusion matrix showing the percentage of mice displaying Class 1, 2 and 3 type recovery from the three AFS subgroups based on the combined evaluation of OF and GW testing results. g. Representative survey IHC images of carrier treated SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes and Cd13-positive immune and stromal cells. h. Quantification of SCI lesion size at 14 days after SCI stratified by subgroup and carrier injection. *p value < 0.05, Two-way ANOVA with Tukey multiple comparison test. i. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup and carrier injection., *p value < 0.02, Two-way ANOVA with Tukey multiple comparison test.

    Article Snippet: The following primary antibodies were used in this study: anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea Pig Gfap (Synaptic Systems, 173 308, 1:500); anti-Goat Cd13 (R&D systems, AF2335, 1:500), anti-Rabbit 5-HT (Serotonin) (Immunostar, #20080, 1:1000); anti- Rat MBP (Sigma, MAB386, 1:500).

    Techniques: Saline, Comparison, Injection

    FIGURE 3 | Revascularization is stabilized by VEGF-E associated with attenuation of neuronal degeneration. (a) Representative fluorescence images of CD31 and PDGFRβ immunolabeling at the injury site in vehicle (VEH)- and VEGF-E-treated mice 4 days after stroke. (b) Analysis of the density of perivascular PDGFRβ+ cells at the injury site 4 days after stroke. (c) Analysis of CD31 and PDGFRβ colocalization at the injury site. (d) Analysis of the number of CD31+ microvascular stalls at the injury site. (e) Representative fluorescence images of CD13 and CD105 immunolabeling at the injury site in VEH- and VEGF-E-treated mice. (f) Analysis of the density of CD105+ microvessels at the injury site. (g) Analysis of CD105 and CD13 colocalization at the injury site. (h) Representative fluorescence images of FJB+ degenerating neurons in the ipsilateral cortex and ipsilateral striatum. Stereological analysis of the density of FJB+ degenerating neurons in the (i) ipsilateral cortex and (j) ipsilateral striatum. Data are boxplot with min/max or stacked histogram (n = 6–7 animals/group). *p < 0.05, **p < 0.01, ***p < 0.001 compared to control (b, d, f, i, unpaired two-tailed t- test). Abbreviations: IF, immunofluorescence; VEGF, vascular endothelial growth factor; VEH, vehicle.

    Journal: The European journal of neuroscience

    Article Title: VEGF-E Attenuates Injury After Ischemic Stroke by Promoting Reparative Revascularization.

    doi: 10.1111/ejn.70114

    Figure Lengend Snippet: FIGURE 3 | Revascularization is stabilized by VEGF-E associated with attenuation of neuronal degeneration. (a) Representative fluorescence images of CD31 and PDGFRβ immunolabeling at the injury site in vehicle (VEH)- and VEGF-E-treated mice 4 days after stroke. (b) Analysis of the density of perivascular PDGFRβ+ cells at the injury site 4 days after stroke. (c) Analysis of CD31 and PDGFRβ colocalization at the injury site. (d) Analysis of the number of CD31+ microvascular stalls at the injury site. (e) Representative fluorescence images of CD13 and CD105 immunolabeling at the injury site in VEH- and VEGF-E-treated mice. (f) Analysis of the density of CD105+ microvessels at the injury site. (g) Analysis of CD105 and CD13 colocalization at the injury site. (h) Representative fluorescence images of FJB+ degenerating neurons in the ipsilateral cortex and ipsilateral striatum. Stereological analysis of the density of FJB+ degenerating neurons in the (i) ipsilateral cortex and (j) ipsilateral striatum. Data are boxplot with min/max or stacked histogram (n = 6–7 animals/group). *p < 0.05, **p < 0.01, ***p < 0.001 compared to control (b, d, f, i, unpaired two-tailed t- test). Abbreviations: IF, immunofluorescence; VEGF, vascular endothelial growth factor; VEH, vehicle.

    Article Snippet: The following primary antibodies were used: rat anti- mouse cluster of differentiation (CD31) (1/500; BD Biosciences, ON, Canada; 550274), goat anti- mouse aminopeptidase N (CD13) (1/250; R&D systems), rat anti- mouse glial fibrillary acidic protein (GFAP) (1/500; Invitrogen, MA, USA; 13- 0300), rabbit anti- mouse ionized calcium binding adaptor molecule (IBA1) (1/500; WAKO, ON, Canada; 019- 19741), goat anti- rat CD45 (1/500; BD Biosciences; 553076), rabbit anti- mouse PDGFRβ (1/250; Abcam, ON, Canada; ab32570), rat anti- mouse endoglin (CD105) (1/250; Novus Biologicals, ON, Canada; NB100- 77666), and rabbit anti- mouse aquaporine- 4 (AQP4) (1/500; Cell Signaling Technology, MA, USA; 59678S).

    Techniques: Fluorescence, Immunolabeling, Control, Two Tailed Test, Immunofluorescence